Dasari Krishna, Alfaro-Murillo Jorge A, Townsend Jeffrey P
bioRxiv. 2025 Jul 25:2024.11.27.625765. doi: 10.1101/2024.11.27.625765.
Tobacco smoke is a known mutagen. However, its physiological effects on the lung may also influence the somatic selective pressures acting on mutations, further shaping cancer evolution. The relative contributions of these mutagenic and physiological effects to oncogenesis have not been quantified, despite their importance in predicting the differential therapeutic effect of targeting variants in lung cancers of smokers and nonsmokers.
We classified 1,722 lung adenocarcinoma (LUAD) sample genomes from The Cancer Genome Atlas and other projects as ever-smoker (ES) or never-smoker (NS) LUAD based on smoking-associated mutational signature attribution or clinical annotation. We then independently calculated background oncogenic mutation rates in the ES- and NS-LUAD groups. Comparing these background rates to observed variant prevalences enabled us to estimate and compare the selective advantages conferred by each mutation in ES- and NS-LUAD. Finally, we quantified pairwise and higher-order epistatic effects by estimating selection for each mutation in specific somatic genotypes.
As expected, background oncogenic mutation rates were gene-specifically elevated in ES-LUAD. However, differences in oncogenic mutation rates between ES- and NS-LUAD were insufficient to explain differences in the prevalence of some mutated genes, implying that such mutations must have further experienced differential somatic selection. In particular, , , and mutations experienced substantially stronger selection in ES-LUAD, whereas mutations of , , , and other genes were more strongly selected in NS-LUAD. Mechanistically, mutations were associated with upregulation of genes involved in the epithelial-mesenchymal transition in NS-LUAD, but not in ES-LUAD. Epistasis was pervasive and distinct between the subtypes: ES-LUAD featured more frequent synergy and substantially less antagonism. These patterns entail divergent evolutionary trajectories, with NS-LUAD constrained to fewer, narrower paths and ES-LUAD exploring a broader, more permissive adaptive landscape. Furthermore, we identified higher-order epistasis-systematically examined here for the first time in cancer-manifesting as sub-additive and emergent synergistic interactions that selectively promote trajectories of oncogenesis.
This disambiguation of the mutagenic and selective effects of tobacco smoke reveals how environmental insult can reshape the evolutionary trajectories of LUAD and enables quantitative prediction of treatment vulnerabilities based on smoking status and tumor somatic genotype.
烟草烟雾是一种已知的诱变剂。然而,其对肺部的生理影响也可能影响作用于突变的体细胞选择压力,进一步塑造癌症的进化。尽管这些诱变和生理效应在预测吸烟者和非吸烟者肺癌中靶向变异的差异治疗效果方面很重要,但它们对肿瘤发生的相对贡献尚未量化。
我们根据与吸烟相关的突变特征归因或临床注释,将来自癌症基因组图谱和其他项目的1722个肺腺癌(LUAD)样本基因组分类为曾经吸烟者(ES)或从不吸烟者(NS)LUAD。然后,我们独立计算ES-LUAD组和NS-LUAD组中的背景致癌突变率。将这些背景率与观察到的变异患病率进行比较,使我们能够估计和比较ES-LUAD和NS-LUAD中每个突变赋予的选择优势。最后,我们通过估计特定体细胞基因型中每个突变的选择来量化成对和高阶上位效应。
正如预期的那样,ES-LUAD中的背景致癌突变率在基因特异性上有所升高。然而,ES-LUAD和NS-LUAD之间致癌突变率的差异不足以解释某些突变基因患病率的差异,这意味着这些突变一定还经历了不同的体细胞选择。特别是, 、 和 突变在ES-LUAD中经历了更强的选择,而 、 、 和其他基因的突变在NS-LUAD中被更强地选择。从机制上讲, 突变与NS-LUAD中参与上皮-间质转化的基因上调有关,但在ES-LUAD中则不然。上位效应普遍存在且在亚型之间不同:ES-LUAD具有更频繁的协同作用和实质上更少的拮抗作用。这些模式导致不同的进化轨迹,NS-LUAD被限制在更少、更窄的路径上,而ES-LUAD探索更广泛、更宽松的适应性景观。此外,我们确定了高阶上位效应——这是首次在癌症中系统地研究——表现为亚加性和新出现的协同相互作用,选择性地促进肿瘤发生轨迹。
对烟草烟雾诱变和选择效应的这种区分揭示了环境损伤如何重塑LUAD的进化轨迹,并能够基于吸烟状态和肿瘤体细胞基因型对治疗易感性进行定量预测。